FDA Determines Regulatory Review Period for ANGIOMAX Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ANGIOMAX, a human drug product, in accordance with federal regulations and law requirements.